A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis
Immune checkpoint inhibitors have revolutionized cancer care. An uncommon, but serious complication, with the use of immune checkpoint inhibitors, is the development of myocarditis. The ATRIUM trial is a randomized trial that is currently enrolling in over 45 centers in the United States and Canada testing whether abatacept will reduce the occurrence of major cardiac events in immune checkpoint inhibitor myocarditis. Additionally, leveraging ATRIUM, is ATRIUM RESCUE, an observational study where patients with immune checkpoint inhibitor myocarditis who are too unwell to be randomized will be administered abatacept and will be followed for outcomes.
